title: MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing.
abstract: Beta-blocker therapy results in a functional benefit in patients with heart failure (CHF) due to idiopathic dilated cardiomyopathy (DCM). This study assessed if similar effects were observed in patients with ischemic heart disease (CAD), NYHA II-III after 6 months of therapy with metoprolol.
  
  
  RESULTS
  Fifty-two patients with CHF secondary to DCM (26 patients) and CAD (26 patients) and a left ventricular ejection fraction (EF)<40% were enrolled in the placebo-controlled study. The study medication was titrated over 6 weeks, the mean final dosage was 135 mg/day. Three patients died due to cardiogenic shock, two received placebo and one metoprolol. Eight patients did not complete the study due to non-compliance. Metoprolol significantly reduced heart rate at rest and after submaximal and maximal exercise. Vo(2)-max and Vo(2)-AT as well as the 6-min walk test improved significantly after metoprolol treatment. There was a significant increase in EF at rest (27.3-35. 2%), submaximal (28.5-37.7%) and maximal exercise (28.7-40.9%) in the metoprolol-treated patients. No differences were found between patients with CAD and DCM. We also observed reduced left ventricular volumes.
  
  
  CONCLUSIONS
  The additional therapy with metoprolol improved cardiac function and the cardiopulmonary exercise capacity in patients with CHF.
authors.affiliation: Department of Medicine II, Johannes Gutenberg-University, Langenbeckstrasse 1, 55131, Mainz, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Genth-Zotz
authors.forename: R J
authors.initials: RJ
authors.lastname: Zotz
authors.forename: M
authors.initials: M
authors.lastname: Sigmund
authors.forename: P
authors.initials: P
authors.lastname: Hanrath
authors.forename: D
authors.initials: D
authors.lastname: Hartmann
authors.forename: M
authors.initials: M
authors.lastname: Böhm
authors.forename: F
authors.initials: F
authors.lastname: Waagstein
authors.forename: N
authors.initials: N
authors.lastname: Treese
authors.forename: J
authors.initials: J
authors.lastname: Meyer
authors.forename: H
authors.initials: H
authors.lastname: Darius
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002306:Cardiac Volume; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000503:physiopathology; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000503:physiopathology; D011446:Prospective Studies; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D008790:Metoprolol